- Home
- AMGN vs ISRG Comparison
AMGN vs ISRG Comparison
Compare AMGN & ISRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- ISRG
- Stock Information
- Founded
- AMGN 1980
- ISRG 1995
- Country
- AMGN United States
- ISRG United States
- Employees
- AMGN N/A
- ISRG N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- ISRG Medical/Dental Instruments
- Sector
- AMGN Health Care
- ISRG Health Care
- Exchange
- AMGN Nasdaq
- ISRG Nasdaq
- Market Cap
- AMGN 156.2B
- ISRG 182.1B
- IPO Year
- AMGN N/A
- ISRG 2000
- Fundamental
- Price
- AMGN $265.86
- ISRG $536.51
- Analyst Decision
- AMGN Buy
- ISRG Strong Buy
- Analyst Count
- AMGN 19
- ISRG 18
- Target Price
- AMGN $324.37
- ISRG $590.59
- AVG Volume (30 Days)
- AMGN 2.7M
- ISRG 1.8M
- Earning Date
- AMGN 05-01-2025
- ISRG 04-22-2025
- Dividend Yield
- AMGN 3.58%
- ISRG N/A
- EPS Growth
- AMGN 56.16
- ISRG 23.31
- EPS
- AMGN 10.94
- ISRG 6.83
- Revenue
- AMGN $34,126,000,000.00
- ISRG $8,714,900,000.00
- Revenue This Year
- AMGN $7.19
- ISRG $17.66
- Revenue Next Year
- AMGN $2.37
- ISRG $15.45
- P/E Ratio
- AMGN $24.29
- ISRG $78.55
- Revenue Growth
- AMGN 15.56
- ISRG 19.08
- 52 Week Low
- AMGN $253.30
- ISRG $379.67
- 52 Week High
- AMGN $346.85
- ISRG $616.00
- Technical
- Relative Strength Index (RSI)
- AMGN 34.80
- ISRG 61.97
- Support Level
- AMGN $268.81
- ISRG $522.95
- Resistance Level
- AMGN $291.61
- ISRG $546.56
- Average True Range (ATR)
- AMGN 7.54
- ISRG 13.68
- MACD
- AMGN -0.76
- ISRG 4.72
- Stochastic Oscillator
- AMGN 0.76
- ISRG 87.72
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About ISRG Intuitive Surgical Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.